Treating obesity: does antagonism of NPY fit the bill?

In this issue of Cell Metabolism, Erondu et al., (2006) identify a selective neuropeptide Y5 receptor antagonist that, as predicted from rodent studies, results in weight loss when administered to overweight and obese human subjects. In a one-year randomized placebo-controlled clinical trial, the weight loss was modest; the results support the emerging concept that NPY acts via overlapping and redundant energy homeostasis pathways.
AuthorsSadaf Farooqi
JournalCell metabolism (Cell Metab) Vol. 4 Issue 4 Pg. 260-2 (Oct 2006) ISSN: 1550-4131 [Print] United States
PMID17011498 (Publication Type: Comment, Journal Article)
Chemical References
  • Anti-Obesity Agents
  • Receptors, Neuropeptide Y
  • neuropeptide Y5 receptor
  • Administration, Oral
  • Animals
  • Anti-Obesity Agents (administration & dosage, pharmacology, therapeutic use)
  • Body Weight
  • Dose-Response Relationship, Drug
  • Humans
  • Models, Biological
  • Obesity (drug therapy)
  • Receptors, Neuropeptide Y (antagonists & inhibitors, metabolism)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: